1. Home
  2. MREO vs VALU Comparison

MREO vs VALU Comparison

Compare MREO & VALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • VALU
  • Stock Information
  • Founded
  • MREO 2015
  • VALU 1931
  • Country
  • MREO United Kingdom
  • VALU United States
  • Employees
  • MREO N/A
  • VALU N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • VALU Investment Managers
  • Sector
  • MREO Health Care
  • VALU Finance
  • Exchange
  • MREO Nasdaq
  • VALU Nasdaq
  • Market Cap
  • MREO 424.5M
  • VALU 384.1M
  • IPO Year
  • MREO N/A
  • VALU N/A
  • Fundamental
  • Price
  • MREO $2.15
  • VALU $39.19
  • Analyst Decision
  • MREO Strong Buy
  • VALU
  • Analyst Count
  • MREO 7
  • VALU 0
  • Target Price
  • MREO $7.71
  • VALU N/A
  • AVG Volume (30 Days)
  • MREO 943.2K
  • VALU 2.8K
  • Earning Date
  • MREO 05-13-2025
  • VALU 07-25-2025
  • Dividend Yield
  • MREO N/A
  • VALU 3.32%
  • EPS Growth
  • MREO N/A
  • VALU 17.96
  • EPS
  • MREO N/A
  • VALU 2.28
  • Revenue
  • MREO N/A
  • VALU $35,695,000.00
  • Revenue This Year
  • MREO N/A
  • VALU N/A
  • Revenue Next Year
  • MREO $54.91
  • VALU N/A
  • P/E Ratio
  • MREO N/A
  • VALU $17.16
  • Revenue Growth
  • MREO N/A
  • VALU N/A
  • 52 Week Low
  • MREO $1.58
  • VALU $32.94
  • 52 Week High
  • MREO $5.02
  • VALU $57.68
  • Technical
  • Relative Strength Index (RSI)
  • MREO 40.94
  • VALU 48.20
  • Support Level
  • MREO $2.12
  • VALU $37.95
  • Resistance Level
  • MREO $2.27
  • VALU $40.00
  • Average True Range (ATR)
  • MREO 0.13
  • VALU 0.62
  • MACD
  • MREO -0.02
  • VALU -0.07
  • Stochastic Oscillator
  • MREO 9.09
  • VALU 40.66

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.

Share on Social Networks: